Daily oral PrEP was preferred over next-generation modalities in a survey of young, cisgender MSM in the United States published in the Journal of the International AIDS Society. Pablo Kokay Valente, PhD, and colleagues conducted an online survey of 737 MSM. The study included a variety of products, including the daily oral pill, an on-demand oral pill taken before and after sexual intercourse, and an injection given every 2 months, as well as products in development: an implant, broadly neutralizing antibodies delivered via IV every 2 months, and a rectal douche used before sexual intercourse that is protective for a few days afterward. Daily oral PrEP was ranked the highest preferred formulation, followed by event-driven oral options and then injectable and implant formulations. Younger people and the uninsured were less likely to prefer injectable or implant forms because of cost and concerns about frequent visits; participants who were more socioeconomically stable were more likely to prefer the new options. “Understanding preferences is important because we need to create interventions that connect people to their preferred delivery method,” Dr. Valente said.